Search Results

Sermonix Pharmaceuticals Inc. today announced that China’s National Medical Products Administration (NMPA) approved the investigational new drug application (IND) for oral lasofoxifene (HLX78 in China) submitted with the assistance of Chinese development partner Shanghai Henlius Biotech, Inc. (2696.HK).

Sermonix Pharmaceuticals Inc. today announced it will present a poster updating the progress of its Phase 3 ELAINE-3 clinical trial at the annual meeting of the American Society of Clinical Oncology (ASCO). ASCO 2024 will be held May 31-June 4, 2024, at McCormick Place in Chicago.

Sermonix Pharmaceuticals Inc. today announced it is now an industry member of the Metastatic Breast Cancer Alliance, a collective of cancer nonprofits, pharmaceutical and biotech industry members and individual patient advocates working collaboratively to transform and improve the lives of people living with mBC.

Sermonix Pharmaceuticals Inc. announced that an article on the effects of its lead investigational drug, oral lasofoxifene, on moderate to severe vaginal atrophy in postmenopausal women was published April 23, 2024 in Menopause: The Journal of The Menopause Society.

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced the publication of its scholarly article, “Lasofoxifene as a Potential Treatment for Aromatase Inhibitor-Resistant ER-Positive Breast Cancer,” in the peer-reviewed journal Breast Cancer Research.

Sermonix Pharmaceuticals Inc. and Shanghai Henlius Biotech, Inc. (2696.HK), today announced a strategic collaboration agreement in which Henlius will receive exclusive rights to develop, manufacture and commercialize Sermonix’s lead investigational drug, lasofoxifene, in China.

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, broadly shared the three poster presentations examining clinical data tied to Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations studies.

Sermonix Pharmaceuticals Inc. today announced that results of its two Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) studies were published in Annals of Oncology, the peer-reviewed journal of the European Society for Medical Oncology (ESMO) and the Japanese Society of Medical Oncology.

Sermonix Pharmaceuticals Inc. today announced it will host a virtual KOL fireside chat on Monday, April 22, 2024 from noon to 1 p.m. ET, featuring Senthil Damodaran, M.D., Ph.D. (MD Anderson Cancer Center) and Seth Wander, M.D., Ph.D. (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer.